To include your compound in the COVID-19 Resource Center, submit it here.

Ablynx’s ambitions

Ablynx adds quality U.S. investors in NASDAQ deal to push biotech’s ambitions

With this week's hefty NASDAQ financing, nanobody company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) not only broadened its U.S. investor base, but added high-quality shareholders that are pushing the company to be even more ambitious as it makes the leap to becoming a commercial play.

Read the full 433 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers